Related Experiment Video
Updated: Mar 29, 2026
05:40
The Motivation for Alcohol Reward: Predictors of Progressive-Ratio Intravenous Alcohol Self-Administration in Humans
Published on: April 28, 2022
3.8K
CYP3A4 activity and haloperidol effects in alcohol addicts
M S Zastrozhin1,2, V V Smirnov3, D A Sychev1
1Russian Medical Academy of Postgraduate Education, Moscow, Russia.
The International Journal of Risk & Safety in Medicine
|December 8, 2015
Summary
This study found that higher CYP3A4 enzyme activity in alcohol abusers correlates with lower haloperidol efficacy and increased side effects. This suggests CYP3A4 plays a key role in haloperidol metabolism, impacting treatment outcomes.
Area of Science:
- Pharmacology and Toxicology
- Clinical Psychiatry
- Addiction Medicine
Background:
- Haloperidol, a common antipsychotic, has variable efficacy and safety profiles in alcohol abusers due to its complex metabolism.
- Cytochrome P450 3A4 (CYP3A4) is a key enzyme involved in haloperidol biotransformation, but its precise role in addiction populations remains unclear.
- Understanding the correlation between CYP3A4 activity and haloperidol's clinical effects is crucial for optimizing treatment in patients with alcohol use disorder.
Purpose of the Study:
- To investigate the relationship between CYP3A4 enzyme activity and the therapeutic efficacy of haloperidol.
- To assess the correlation between CYP3A4 activity and the safety profile of haloperidol treatment.
- To examine these correlations specifically in male alcohol abusers during addiction exacerbation.
Main Methods:
- A cohort of 15 male alcohol abusers hospitalized during addiction exacerbation received haloperidol.
- CYP3A4 activity was quantified using the cortisol/6-beta-hydroxycortisol ratio in urine via HPLC/MS.
- Treatment efficacy and safety were evaluated using standardized psychometric scales (addiction severity, anxiety, side effects).
Main Results:
- A moderate inverse correlation was observed between CYP3A4 activity and addiction severity (r=-0.36), anxiety (r=-0.45), and side effects (r=-0.15) in the overall group.
- In patients receiving higher haloperidol doses (>7.5mg oral or >5mg injectable daily), a strong inverse correlation was found between CYP3A4 activity and addiction severity (r=-0.68), anxiety (r=-0.71), and side effects (r=-0.76).
- These findings indicate that higher CYP3A4 activity is associated with reduced haloperidol efficacy and increased adverse events.
Conclusions:
- CYP3A4 activity significantly correlates with both the efficacy and safety of haloperidol in alcohol-dependent patients during acute addiction.
- The inverse relationship suggests that increased CYP3A4 activity diminishes haloperidol's effectiveness, potentially due to accelerated metabolism.
- Further research with larger cohorts is warranted to confirm these findings and explore therapeutic implications.
Related Concept Videos
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
869
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
869
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
344
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
344
01:27CNS Depressants: Alcohol and Nicotine
1.5K
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
1.5K
01:28Depressants
576
Depressant drugs, including alcohol and sedative-hypnotics, diminish central nervous system activity by enhancing the action of gamma-aminobutyric acid (GABA), a neurotransmitter that reduces brain activity and promotes relaxation. These substances can have various therapeutic uses but also pose significant risks, especially when misused or combined.
Alcohol is a common depressant that can induce a sense of relaxation and reduced inhibition at low doses. Contrary to its occasional...
Alcohol is a common depressant that can induce a sense of relaxation and reduced inhibition at low doses. Contrary to its occasional...
576
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
155
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
155
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
281
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
281